ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsUnmet Needs in LDL-C Lowering: When Statins Won't Do!PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabPCSK9 inhibitors in the prevention of cardiovascular diseaseThe year in cardiology 2015: preventionPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaVery low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateEffect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO IIPCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.Alirocumab (Praluent): First in the New Class of PCSK9 InhibitorsEfficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol.Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.My Approach to the Patient With Familial Hypercholesterolemia.Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trialsLong-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?Replacing statins with PCSK9-inhibitors and delaying treatment until 18 years of age in patients with familial hypercholesterolaemia is not a good idea.Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.PCSK9 in chronic kidney disease.Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.PCSK9 inhibitors: A new era of lipid lowering therapy.PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
P2860
Q26741078-5777F081-66FC-41CD-AD4F-9B780E536442Q26741705-374E83F8-A510-41D4-B5DF-5A5AF159EF2DQ26747776-99517C45-D7E3-47ED-8FC9-F86D123D7B28Q28071452-80B7C198-C9C7-4826-9B30-19DA26E32849Q28072221-8615D11E-A0E6-4B96-8D34-2623F3C2EFF5Q28073656-627F2FC8-FCB7-43C0-B393-BC53EC29FDF4Q28275648-64106D3E-AEC0-4C4F-A263-951ED269BE14Q30244599-4625F386-8B12-4F80-8C1E-8974B5DD16A1Q33590874-3AAA9725-6C40-48C9-8512-E9B8050BF138Q33599961-EBC1BF57-C052-402C-928B-4CBC140133E7Q33670893-20E354FB-021F-4870-9EAF-47339214D1BBQ33808620-2122EFBF-BB50-4EC2-808B-5AD2C4922FDDQ33835866-D0433F31-F622-4287-9BC1-0CBAF1F8F011Q33904455-117C2EEB-A564-4687-A58C-9EA63A2DD982Q34536594-B1864161-56C2-4783-87D5-EC7F2A89773CQ35999550-02329C65-0A1B-49D9-B100-651ACFE9002AQ36091331-5605F7D2-6D06-4EB6-8C06-FBA8F5BC143AQ36130225-E9BA3EE3-E80B-4C21-990A-E9AA4571BC99Q36425306-FA83D2D4-8249-45DC-B44A-B3C251795551Q37364393-6553E2E6-5FF6-4132-8E41-C341EA59BFCCQ37367952-9DA11FAB-CE82-4BBE-B674-B466DC9E8750Q37488469-8FF1F809-D90C-4297-BEC5-66B40185F40EQ37584256-6857BCE5-106B-4815-8336-8D2AC208C0E8Q37591607-12A2C40C-E552-445C-A672-FED2995C69E5Q37591725-092395F1-73ED-41A4-A079-B43012F96400Q37603961-A939D766-14BD-409C-8040-2244D09668A5Q37731770-6D4BD65F-03F8-4818-8070-C77EB0628715Q37736674-B5492849-15F6-4D4D-A686-2B409E5228D2Q38379459-45619D57-1541-4E41-8143-91F3651F7BBFQ38597940-2D900B80-350B-459F-B037-6D309C75EB4EQ38657213-9AEB0AF7-C0AF-403E-A96B-820E0E5CA958Q38724969-1C5C4C0A-D9EB-46C6-BB92-3D16D5CD74FFQ38793246-38F134B1-9ED4-4D3E-9D84-B62320109C49Q38938935-DA37F3CF-344B-4E1C-A0B8-97140C2C1E0AQ39022581-C7496F8F-D837-439B-B4E7-CD5BDB951480Q39034676-9186ADDE-7B93-4FFC-BD87-8A489FA8F09FQ39176815-5A171732-4692-476F-B2E0-CD5F9C6128DFQ39393317-5C9CF9D0-5440-4E5C-8D13-681F836E4DE2Q39443793-C3B985EB-D641-40AD-80DD-17C70460A59CQ40100018-F89FB11D-1076-47CF-8807-1B39D87DDCC9
P2860
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@ast
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@en
type
label
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@ast
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@en
prefLabel
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@ast
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@en
P2093
P2860
P50
P356
P1476
ODYSSEY FH I and FH II: 78 wee ...... familial hypercholesterolaemia
@en
P2093
Christelle Lorenzato
Daniel A Gipe
Fernando Civeira
G Kees Hovingh
Gisle Langslet
Henry N Ginsberg
John J P Kastelein
Marie T Baccara-Dinet
Mary Jane Geiger
P2860
P304
P356
10.1093/EURHEARTJ/EHV370
P577
2015-09-01T00:00:00Z